|
Jun 18, 2021
|
Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grant of a non-statutory stock option to one new employee in connection with the
|
|
Jun 2, 2021
|
Sesen Bio Announces Global Supply Partnership with Qilu Pharmaceutical
Technology transfer to Qilu Pharmaceutical on track for completion in 2021 Sesen Bio to receive $2M milestone payment upon completion of technology transfer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein
|
|
Jun 1, 2021
|
Sesen Bio Strengthens Senior Leadership Team
Company hires four experienced leaders across commercial, medical and human resources functions as it works towards launch readiness Company remains on track for potential approval of Vicineum™ in the US in August 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.
|
|
May 27, 2021
|
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Participate in Fireside Chat at the 2021 Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 27, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Sesen Bio President and CEO Dr.
|
|
May 21, 2021
|
Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 21, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grant of a non-statutory stock option to one new employee in connection with the
|
|
May 10, 2021
|
Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™
Strengthened balance sheet with $110M in cash and cash equivalents as of March 31, 2021 Company remains on track for potential approval in the US in August 2021 and in Europe in early 2022 Company to host conference call at 8am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 10, 2021-- Sesen Bio
|
|
May 4, 2021
|
Sesen Bio Announces Commercial Launch Readiness Progress as the Company Approaches the Potential Approval and Launch of Vicineum™
Company appoints experienced commercial leader, Lisa LaMond , to oversee sales strategy and execution Selected Syneos Health ® as partner for field sales execution in the US Company remains on track for potential approval in the US in August 2021 CAMBRIDGE, Mass.
|
|
May 3, 2021
|
Sesen Bio to Host Conference Call to Review First Quarter 2021 Financial Results and Provide Business Update on Monday, May 10, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company’s management team will host a conference call to review operating
|
|
Apr 16, 2021
|
Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the grants of non-statutory stock options to four new employees in connection with
|
|
Apr 8, 2021
|
Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity “Horizons in Oncology” Virtual Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 8, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the Canaccord Genuity “Horizons in
|
